401 related articles for article (PubMed ID: 11106587)
1. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.
Kuperwasser C; Hurlbut GD; Kittrell FS; Dickinson ES; Laucirica R; Medina D; Naber SP; Jerry DJ
Am J Pathol; 2000 Dec; 157(6):2151-9. PubMed ID: 11106587
[TBL] [Abstract][Full Text] [Related]
2. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice.
Backlund MG; Trasti SL; Backlund DC; Cressman VL; Godfrey V; Koller BH
Cancer Res; 2001 Sep; 61(17):6577-82. PubMed ID: 11522657
[TBL] [Abstract][Full Text] [Related]
3. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain.
Blackburn AC; McLary SC; Naeem R; Luszcz J; Stockton DW; Donehower LA; Mohammed M; Mailhes JB; Soferr T; Naber SP; Otis CN; Jerry DJ
Cancer Res; 2004 Aug; 64(15):5140-7. PubMed ID: 15289317
[TBL] [Abstract][Full Text] [Related]
4. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development.
Jerry DJ; Kittrell FS; Kuperwasser C; Laucirica R; Dickinson ES; Bonilla PJ; Butel JS; Medina D
Oncogene; 2000 Feb; 19(8):1052-8. PubMed ID: 10713689
[TBL] [Abstract][Full Text] [Related]
5. Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/- mice.
Dunphy KA; Blackburn AC; Yan H; O'Connell LR; Jerry DJ
Breast Cancer Res; 2008; 10(3):R43. PubMed ID: 18471300
[TBL] [Abstract][Full Text] [Related]
6. Effects of genetic background on tumorigenesis in p53-deficient mice.
Donehower LA; Harvey M; Vogel H; McArthur MJ; Montgomery CA; Park SH; Thompson T; Ford RJ; Bradley A
Mol Carcinog; 1995 Sep; 14(1):16-22. PubMed ID: 7546219
[TBL] [Abstract][Full Text] [Related]
7. Atm heterozygous deficiency enhances development of mammary carcinomas in p53 heterozygous knockout mice.
Umesako S; Fujisawa K; Iiga S; Mori N; Takahashi M; Hong DP; Song CW; Haga S; Imai S; Niwa O; Okumoto M
Breast Cancer Res; 2005; 7(1):R164-70. PubMed ID: 15642165
[TBL] [Abstract][Full Text] [Related]
8. Genetic and stochastic influences upon tumor formation and tumor types in Li-Fraumeni mouse models.
Chan CS; Sun Y; Ke H; Zhao Y; Belete M; Zhang C; Feng Z; Levine AJ; Hu W
Life Sci Alliance; 2021 Mar; 4(3):. PubMed ID: 33376133
[No Abstract] [Full Text] [Related]
9. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
10. Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis.
Loehberg CR; Thompson T; Kastan MB; Maclean KH; Edwards DG; Kittrell FS; Medina D; Conneely OM; O'Malley BW
Cancer Res; 2007 Dec; 67(24):12026-33. PubMed ID: 18089834
[TBL] [Abstract][Full Text] [Related]
11. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
12. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53.
Koch JG; Gu X; Han Y; El-Naggar AK; Olson MV; Medina D; Jerry DJ; Blackburn AC; Peltz G; Amos CI; Lozano G
Mamm Genome; 2007 May; 18(5):300-9. PubMed ID: 17557176
[TBL] [Abstract][Full Text] [Related]
13. Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
Nemunaitis JM; Nemunaitis J
Future Oncol; 2008 Dec; 4(6):759-68. PubMed ID: 19086841
[TBL] [Abstract][Full Text] [Related]
14. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.
Brodie SG; Xu X; Qiao W; Li WM; Cao L; Deng CX
Oncogene; 2001 Nov; 20(51):7514-23. PubMed ID: 11709723
[TBL] [Abstract][Full Text] [Related]
15. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
16. Genetic mapping of a putative tumor suppressor locus that influences tumorigenesis and metastasis in mice.
Ayanga B; Price R; Gu X; Lozano G; Evans SC
Genes Chromosomes Cancer; 2006 Jul; 45(7):668-75. PubMed ID: 16586494
[TBL] [Abstract][Full Text] [Related]
17. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
19. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.
Venkatachalam S; Shi YP; Jones SN; Vogel H; Bradley A; Pinkel D; Donehower LA
EMBO J; 1998 Aug; 17(16):4657-67. PubMed ID: 9707425
[TBL] [Abstract][Full Text] [Related]
20. Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells.
Goepfert TM; McCarthy M; Kittrell FS; Stephens C; Ullrich RL; Brinkley BR; Medina D
FASEB J; 2000 Nov; 14(14):2221-9. PubMed ID: 11053243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
